Cognitive enhancement therapy for a model of Down syndrome.
Down syndrome is a complex condition that results from having a third copy of human chromosome 21. People with the syndrome experience problems with learning and memory that affect many aspects of their lives. In this issue of Science Translational Medicine, Salehi et al. report on successful drug treatment of learning deficits in an animal model of Down syndrome. This study highlights the function of the norepinephrine-ergic system in Down syndrome and suggests possible treatment options for people with Down syndrome.
Wiseman
Frances K
FK
Department of Neurodegenerative Disease, University College London, Institute of Neurology, Queen Square, London WC1N 3BG, UK. f.wiseman@prion.ucl.ac.uk
D000818:Animals; D003071:Cognition; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000503:physiopathology / Q000523:psychology*; D006801:Humans; D051379:Mice; D008962:Models, Theoretical; D009638:Norepinephrine / Q000502:physiology; D015398:Signal Transduction
D009638:Norepinephrine